Browse Studies — Arctuva

Phase 3

A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer

This Phase 3 study will be conducted in different countries around the world with up to about 688 participants. The purpose of this study is to evaluate how w…

Platinum-Sensitive Ovarian CancerOvarian Cancer

Estimated

~$10 – $7,500

GenmabNCT07564141

Phase 3

A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L Platinum-Based Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)

This Phase 3 study will be conducted in different countries around the world with up to about 544 participants. The purpose of this study is to evaluate how w…

Ovarian CancerPlatinum-sensitive Ovarian CancerPSOC

Estimated

~$10 – $7,500

GenmabNCT07225270

Phase 2

A Phase 1b Dose Escalation and Expansion Study of IMGN151 as Monotherapy and in Combination With Other Anti-Cancer Therapies in Subjects With Gynecologic Cancers

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety and tolerability …

Gynecologic CancersPlatinum-Sensitive Ovarian CancerFallopian Tube Cancer+1 more

Estimated

~$10 – $7,500

AbbVieNCT07024784